Laura Toso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Laura Toso has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Catherine Y. Spong
National Institute of Child and Human Development, National Institutes of Health, Bethesda, Maryland; the 2Department of Obstetrics and Gynecology, George Washington University, Washington, DC; and the 3Department of Obstetrics and Gynaecology, University of Milano-Bicocca, Ospedale S. Gerardo, Monza, Italy
5 shared publicationsDaniel Abebe
National Institute of Child and Human Development, National Institutes of Health, Bethesda, Maryland; the 2Department of Obstetrics and Gynecology, George Washington University, Washington, DC; and the 3Department of Obstetrics and Gynaecology, University of Milano-Bicocca, Ospedale S. Gerardo, Monza, Italy
5 shared publicationsRobin Roberson
National Institute of Child and Human Development, National Institutes of Health, Bethesda, Maryland; the 2Department of Obstetrics and Gynecology, George Washington University, Washington, DC; and the 3Department of Obstetrics and Gynaecology, University of Milano-Bicocca, Ospedale S. Gerardo, Monza, Italy
5 shared publicationsJade Woodard
3 shared publicationsJane Park
Unit on Perinatal and Developmental Neurobiology, National Institute of Child and Human Development
3 shared publicationsSarah H. Poggi
Department of Obstetrics and Gynecology, INOVA Hospital, Alexandria, VA
2 shared publications
Latest Publications
- 1 December 2008
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 112 (6) , 1242-1251
Prevention of Developmental Delays in a Down Syndrome Mouse Model
OBJECTIVE: To estimate whether prenatal treatment with neuroprotective peptides prevents the developmental delay and the glial deficit in the Ts65Dn mouse model for Down syndrome and to explore the peptides’ effects on achievement of normal development. METHODS: Pregnant Ts65Dn females were randomly assigned to NAPVSIPQ+SALLRSIPA or control and were treated by investigators blinded to treatment and genotype on gestational days 8–12. Offspring were tested from postnatal day 5 to 21 for motor and sensory milestones with standardized tests by operators blinded to the pup’s treatment and genotype. The pup’s genotype was determined after completion of all tests. Activity-dependent neurotrophic factor, glial fibrillary acidic protein, and vasoactive intestinal peptide expression were determined using real-time polymerase chain reaction. RESULTS: Trisomic mice achieved milestones with a significant delay in four of five motor and sensory milestones. Trisomic mice that were prenatally exposed to NAPVSIPQ+SALLRSIPA achieved developmental milestones at the same time as the controls in three of four motor and one of four sensory milestones (P<.01). Euploid pups prenatally treated with NAPVSIPQ+SALLRSIPA achieved developmental milestones significantly earlier than the euploid pups prenatally treated with placebo. Activity-dependent neurotrophic factor expression was significantly downregulated in the Ts65Dn brains compared with the controls, prenatal treatment with NAPVSIPQ+ SALLRSIPA prevented the activity-dependent neurotrophic factor decrease in the Ts65Dn brains, and the expression was not different from the controls. The glial marker glial fibrillary acidic protein demonstrated the known glial deficit in the Ts65Dn mice, and treatment with NAPVSIPQ+ SALLRSIPA prevented its downregulation. Lastly, vasoactive intestinal peptide levels were increased in the trisomic brains, whereas treatment with NAPVSIPQ+SALLRSIPA did not prevent its upregulation. CONCLUSION: Prenatal treatment with NAPVSIPQ and SALLRSIPA prevented developmental delay and the glial deficit in Down syndrome. These findings highlight a possibility for the prevention of developmental sequelae in Down syndrome and suggest a potential intervention during pregnancy that may improve the outcome.
- 1 December 2008
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 112 (6) , 1242-1251
Prevention of Developmental Delays in a Down Syndrome Mouse Model
OBJECTIVE: To estimate whether prenatal treatment with neuroprotective peptides prevents the developmental delay and the glial deficit in the Ts65Dn mouse model for Down syndrome and to explore the peptides’ effects on achievement of normal development. METHODS: Pregnant Ts65Dn females were randomly assigned to NAPVSIPQ+SALLRSIPA or control and were treated by investigators blinded to treatment and genotype on gestational days 8–12. Offspring were tested from postnatal day 5 to 21 for motor and sensory milestones with standardized tests by operators blinded to the pup’s treatment and genotype. The pup’s genotype was determined after completion of all tests. Activity-dependent neurotrophic factor, glial fibrillary acidic protein, and vasoactive intestinal peptide expression were determined using real-time polymerase chain reaction. RESULTS: Trisomic mice achieved milestones with a significant delay in four of five motor and sensory milestones. Trisomic mice that were prenatally exposed to NAPVSIPQ+SALLRSIPA achieved developmental milestones at the same time as the controls in three of four motor and one of four sensory milestones (P<.01). Euploid pups prenatally treated with NAPVSIPQ+SALLRSIPA achieved developmental milestones significantly earlier than the euploid pups prenatally treated with placebo. Activity-dependent neurotrophic factor expression was significantly downregulated in the Ts65Dn brains compared with the controls, prenatal treatment with NAPVSIPQ+ SALLRSIPA prevented the activity-dependent neurotrophic factor decrease in the Ts65Dn brains, and the expression was not different from the controls. The glial marker glial fibrillary acidic protein demonstrated the known glial deficit in the Ts65Dn mice, and treatment with NAPVSIPQ+ SALLRSIPA prevented its downregulation. Lastly, vasoactive intestinal peptide levels were increased in the trisomic brains, whereas treatment with NAPVSIPQ+SALLRSIPA did not prevent its upregulation. CONCLUSION: Prenatal treatment with NAPVSIPQ and SALLRSIPA prevented developmental delay and the glial deficit in Down syndrome. These findings highlight a possibility for the prevention of developmental sequelae in Down syndrome and suggest a potential intervention during pregnancy that may improve the outcome.
- 1 August 2006
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 195 (2) , 522-527
Prenatal alcohol exposure alters GABAAα5 expression: A mechanism of alcohol-induced learning dysfunction
- 1 August 2006
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 195 (2) , 522-527
Prenatal alcohol exposure alters GABAAα5 expression: A mechanism of alcohol-induced learning dysfunction
- 1 March 2006
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 194 (3) , 681-686
Prevention of alcohol-induced learning deficits in fetal alcohol syndrome mediated through NMDA and GABA receptors
- 1 March 2006
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 194 (3) , 681-686
Prevention of alcohol-induced learning deficits in fetal alcohol syndrome mediated through NMDA and GABA receptors
- 1 October 2005
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 193 (4) , 1534-1539
N-Methyl-D-aspartate subunit expression during mouse development altered by in utero alcohol exposure
- 1 October 2005
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 193 (4) , 1534-1539
N-Methyl-D-aspartate subunit expression during mouse development altered by in utero alcohol exposure
- 1 September 2005
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 193 (3) , 933-941
Inflammatory-mediated model of cerebral palsy with developmental sequelae
- 1 September 2005
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 193 (3) , 933-941
Inflammatory-mediated model of cerebral palsy with developmental sequelae